{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:28:01Z","timestamp":1791948481494,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Janssen Cilag, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1111\/bjd.14338","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T13:53:36Z","timestamp":1449582816000},"page":"839-846","source":"Crossref","is-referenced-by-count":171,"title":["Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum"],"prefix":"10.1093","volume":"174","author":[{"given":"J.L.","family":"Blok","sequence":"first","affiliation":[{"name":"Department of Dermatology; University Medical Center Groningen; Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Li","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, LLC; Spring House PA U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brodmerkel","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, LLC; Spring House PA U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Horv\u00e1tovich","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Analytical Biochemistry; Faculty of Mathematics and Natural Sciences; University of Groningen; Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Jonkman","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University Medical Center Groningen; Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University Medical Center Groningen; Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"key":"10.1111\/bjd.14338-BIB0001|bjd14338-cit-0001","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"Revuz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14338-BIB0002|bjd14338-cit-0002","first-page":"729","volume-title":"Dermatologic Surgery (Roenigh RK","author":"Hurley","year":"1989"},{"key":"10.1111\/bjd.14338-BIB0003|bjd14338-cit-0003","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2340\/00015555-0866","article-title":"Psychophysical aspects of hidradenitis suppurativa","volume":"90","author":"Matusiak","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.14338-BIB0004|bjd14338-cit-0004","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","article-title":"Quality of life impairment in hidradenitis suppurativa: a study of 61 cases","volume":"56","author":"Wolkenstein","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14338-BIB0005|bjd14338-cit-0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14338-BIB0006|bjd14338-cit-0006","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","article-title":"Association of metabolic syndrome and hidradenitis suppurativa","volume":"150","author":"Miller","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.14338-BIB0007|bjd14338-cit-0007","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjd.12233","article-title":"Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support","volume":"168","author":"Danby","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0008|bjd14338-cit-0008","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0009|bjd14338-cit-0009","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14338-BIB0010|bjd14338-cit-0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14338-BIB0011|bjd14338-cit-0011","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjd.12104","article-title":"Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review","volume":"168","author":"Blok","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0012|bjd14338-cit-0012","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1111\/bjd.14338-BIB0013|bjd14338-cit-0013","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"10.1111\/bjd.14338-BIB0014|bjd14338-cit-0014","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cyto.2013.03.008","article-title":"Haplotypes of IL-12R\u03b21 impact on the clinical phenotype of hidradenitis suppurativa","volume":"62","author":"Giatrakos","year":"2013","journal-title":"Cytokine"},{"key":"10.1111\/bjd.14338-BIB0015|bjd14338-cit-0015","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/bjd.14338-BIB0016|bjd14338-cit-0016","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/bjd.14338-BIB0017|bjd14338-cit-0017","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2340\/00015555-1229","article-title":"Management of recalcitrant hidradenitis suppurativa with ustekinumab","volume":"92","author":"Sharon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.14338-BIB0018|bjd14338-cit-0018","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14338-BIB0019|bjd14338-cit-0019","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.14338-BIB0020|bjd14338-cit-0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jdv.12438","article-title":"Use of biological treatments in patients with hidradenitis suppurativa","volume":"29","author":"Martin-Ezquerra","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14338-BIB0021|bjd14338-cit-0021","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","article-title":"Ustekinumab for hidradenitis suppurativa: a case report","volume":"105","author":"Santos-P\u00e9rez","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1111\/bjd.14338-BIB0022|bjd14338-cit-0022","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0023|bjd14338-cit-0023","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/jid.2011.138","article-title":"Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life","volume":"131","author":"Prinsen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14338-BIB0024|bjd14338-cit-0024","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14338-BIB0025|bjd14338-cit-0025","first-page":"997","article-title":"The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0026|bjd14338-cit-0026","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","author":"Kimball","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14338-BIB0027|bjd14338-cit-0027","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/09546634.2011.571657","article-title":"Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa","volume":"23","author":"van Rappard","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.14338-BIB0028|bjd14338-cit-0028","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjd.12105","article-title":"Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa","volume":"168","author":"Savva","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0029|bjd14338-cit-0029","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2006.07.027","article-title":"Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients","volume":"56","author":"Fardet","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14338-BIB0030|bjd14338-cit-0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.14338-BIB0031|bjd14338-cit-0031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cyto.2015.03.009","article-title":"Regulation of IL-17 in atherosclerosis and related autoimmunity","volume":"74","author":"Ryu","year":"2015","journal-title":"Cytokine"},{"key":"10.1111\/bjd.14338-BIB0032|bjd14338-cit-0032","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/13547500903075218","article-title":"Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging","volume":"14","author":"Matusiak","year":"2009","journal-title":"Biomarkers"},{"key":"10.1111\/bjd.14338-BIB0033|bjd14338-cit-0033","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/bjd.12234","article-title":"Myeloid marker S100A8\/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?","volume":"168","author":"Wieland","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0034|bjd14338-cit-0034","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/1346-8138.12803","article-title":"Sex hormones in male psoriasis patients and their correlation with the Psoriasis Area and Severity Index","volume":"42","author":"Cemil","year":"2015","journal-title":"J Dermatol"},{"key":"10.1111\/bjd.14338-BIB0035|bjd14338-cit-0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/bmj.292.6515.245","article-title":"Mediation of hidradenitis suppurativa by androgens","volume":"292","author":"Mortimer","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1111\/bjd.14338-BIB0036|bjd14338-cit-0036","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/bjs.1800721223","article-title":"Hidradenitis suppurativa: evidence for an endocrine abnormality","volume":"72","author":"Harrison","year":"1985","journal-title":"Br J Surg"},{"key":"10.1111\/bjd.14338-BIB0037|bjd14338-cit-0037","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/thoraxjnl-2011-200234","article-title":"Leukotriene A4 hydrolase: an anti-inflammatory role for a proinflammatory enzyme","volume":"66","author":"Snelgrove","year":"2011","journal-title":"Thorax"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14338","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.14338\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:18:29Z","timestamp":1676366309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/174\/4\/839\/6617896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,27]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.14338","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725996464.793534538","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,27]]}}}